Form 4: Sangamo Exec's Stock Disposition for Tax Withholding

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of 6,708 shares of common stock for mandatory tax withholding purposes following an RSU vesting event.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc. (SGMO), reported a disposition of common stock.
• The transaction involved 6,708 shares of common stock, surrendered for mandatory tax withholding purposes.
• The shares were surrendered at a price of $0.66 per share, based on the Issuer's closing stock price on October 22, 2025.
• This disposition was not a discretionary trade but a required action pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan.
• Following this transaction, Mr. Davis beneficially owns 194,514 shares of common stock.
• The beneficial ownership includes shares from various Restricted Stock Unit (RSU) grants with future vesting schedules through January 2026 and February 2026, and beyond for a February 2025 grant.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting, not indicative of a positive or negative discretionary action by the insider or the company's performance.

Positives

• The transaction is a non-discretionary disposition solely for mandatory tax withholding, indicating no active sale decision by the executive.
• The executive retains a substantial beneficial ownership of 194,514 shares, demonstrating continued alignment with shareholder interests.

Negatives

• The executive's direct beneficial ownership decreased by 6,708 shares due to the tax withholding.

Risks

• The value of the executive's remaining RSU grants and beneficial ownership is subject to the future performance and stock price of Sangamo Therapeutics, Inc.

Future Outlook

The filing details future vesting schedules for various RSU grants held by the reporting person, with installments extending through January 2026, February 2026, and beyond for a February 2025 grant, all contingent on continuous service.

Industry Context

This filing is a routine insider transaction report (Form 4) common across all publicly traded companies, reflecting compensation practices involving equity awards and mandatory tax obligations upon vesting. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a sale reflecting management's view on stock performance.
• Employees: Reflects standard equity compensation practices for executives, which can be a positive for employee retention and motivation.

Next Steps

• Remaining shares from the January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026.
• Remaining shares from the February 24, 2023 RSU grant will vest in successive equal quarterly installments through February 24, 2026.
• One-quarter of the shares from the February 25, 2025 RSU grant will vest on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares for mandatory tax withholding upon RSU vesting. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The executive's continued significant beneficial ownership also suggests ongoing alignment with company success. Therefore, a 'hold' recommendation is appropriate as the filing itself does not alter the fundamental investment thesis.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, RSU, Stock Disposition, Tax Withholding, Gregory D. Davis, Equity Incentive Plan